Doubleverify Holdings Insider Sold Shares Worth $354,576, According to a Recent SEC Filing-March 2024-www.financetom.com

Doubleverify Holdings Insider Sold Shares Worth $354,576, According to a Recent SEC Filing

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Doubleverify Holdings Insider Sold Shares Worth $354,576, According to a Recent SEC Filing

Mar 27, 2024 1:54 PM

04:21 PM EDT, 03/27/2024 (MT Newswires) -- Nicola T Allais, Chief Financial Officer, on March 25, 2024, sold 10,584 shares in Doubleverify Holdings ( DV ) for $354,576. Following the Form 4 filing with the SEC, Allais has control over a total of 73,030 shares of the company, with 73,030 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1819928/000120919124005100/xslF345X03/doc4.xml

Price: 32.7, Change: -0.21, Percent Change: -0.64

Previous page： Update: Boeing Reportedly Withdraws Pay Offer to Striking Union, Halts Talks Next page： DiaMedica Says It Receives South Africa Approval to Start Mid-Stage Trial for Preeclampsia Treatment

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Update: Boeing Reportedly Withdraws Pay Offer to Striking Union, Halts Talks

Oct 10, 2024

09:13 AM EDT, 10/09/2024 (MT Newswires) -- (Updates with details from Boeing's ( BA ) statement in the first and second paragraphs.) Boeing ( BA ) said Wednesday it has withdrawn its recent pay offer of a 30% raise to about 33,000 US workers as negotiations with the striking union broke down. In a letter to employees, Boeing ( BA...

DiaMedica Says It Receives South Africa Approval to Start Mid-Stage Trial for Preeclampsia Treatment

Oct 10, 2024

09:12 AM EDT, 10/09/2024 (MT Newswires) -- DiaMedica Therapeutics ( DMAC ) said Wednesday that it has received regulatory approval from the South African Health Products Regulatory Authority to begin a mid-stage clinical trial with DM199 to treat preeclampsia. The company said it will conduct the planned two-part mid-stage trial at Tygerberg Hospital in Cape Town, South Africa. DiaMedica said...

Sonnet BioTherapeutics Signs Licensing Deal for SON-080 in India; Shares Rise Pre-Bell

Oct 10, 2024

09:27 AM EDT, 10/09/2024 (MT Newswires) -- Sonnet BioTherapeutics ( SONN ) said Wednesday it has signed a licensing agreement with Alkem Laboratories on SON-080, which is intended for the treatment of diabetic peripheral neuropathy in India. Under the terms of the agreement, Alkem will pay Sonnet an upfront payment of $1 million, as well as up to an additional...

Hurricane impact on Baxter to further constrain IV fluid supply, HHS says

Oct 10, 2024

Oct 9 (Reuters) - Hurricane Helene's impact on Baxter International's ( BAX ) facility will likely lead to further constraints in the supply of intravenous fluids, the U.S. Department of Health and Human Services said on Wednesday. On Sept. 29, medical device maker Baxter said its North Cove site which makes IV fluids, had been affected by hurricane-related flooding and...